Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance
DOI10.1111/BIOM.12324zbMATH Open1419.62448OpenAlexW1560956491WikidataQ36955813 ScholiaQ36955813MaRDI QIDQ2803513FDOQ2803513
Authors: Ivair Silva, M. Kulldorff
Publication date: 4 May 2016
Published in: Biometrics (Search for Journal in Brave)
Full work available at URL: http://europepmc.org/articles/pmc4888780
Recommendations
- Continuous post-market sequential safety surveillance with minimum events to signal
- Type I error probability spending for post-market drug and vaccine safety surveillance with Poisson data
- Exact conditional maximized sequential probability ratio test adjusted for covariates
- A maximized sequential probability ratio test for drug and vaccine safety surveillance
- Wither group-sequential or time-sequential interim analysis in clinical trials?
exact sequential analysisexpected time to signalpost-market safety surveillanceuniformly better sequential design
Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical analysis (62L10)
Cites Work
- Title not available (Why is that?)
- Sequential Tests of Statistical Hypotheses
- A maximized sequential probability ratio test for drug and vaccine safety surveillance
- A sequential clinical trial for testing \(p_1=p_2\)
- Title not available (Why is that?)
- Title not available (Why is that?)
- Testing one Simple Hypothesis Against Another
- Statistical monitoring of clinical trials. A unified approach.
- Curtailment in single-arm two-stage phase II oncology trials
Cited In (11)
- Nearly optimal truncated group sequential test on binomial proportions
- Complementary hypotheses in safety surveillance
- A maximized sequential probability ratio test for drug and vaccine safety surveillance
- A seasonality-adjusted sequential test for vaccine safety surveillance
- Alpha spending for historical versus surveillance Poisson data with CMaxSPRT
- Exact sequential test for clinical trials and post-market drug and vaccine safety surveillance with Poisson and binary data
- Two-sample two-stage and purely sequential methodologies for tests of hypotheses with applications: comparing normal means when the two variances are unknown and unequal
- The person-time ratio distribution for the exact monitoring of adverse events: historical vs surveillance Poisson data
- Type I error probability spending for post-market drug and vaccine safety surveillance with Poisson data
- Exact conditional maximized sequential probability ratio test adjusted for covariates
- Frequentist-Bayesian Monte Carlo test for mean vectors in high dimension
Uses Software
This page was built for publication: Continuous versus group sequential analysis for post-market drug and vaccine safety surveillance
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2803513)